DK0850243T3 - O-Glycaninhibitorer af selectinmedieret inflammation - Google Patents

O-Glycaninhibitorer af selectinmedieret inflammation

Info

Publication number
DK0850243T3
DK0850243T3 DK96928073T DK96928073T DK0850243T3 DK 0850243 T3 DK0850243 T3 DK 0850243T3 DK 96928073 T DK96928073 T DK 96928073T DK 96928073 T DK96928073 T DK 96928073T DK 0850243 T3 DK0850243 T3 DK 0850243T3
Authority
DK
Denmark
Prior art keywords
glycans
selectin
glycan
beta
disialylated
Prior art date
Application number
DK96928073T
Other languages
Danish (da)
English (en)
Inventor
P Mcever Rodger
D Cummings Richard
L Moore Kevin
Original Assignee
Univ Oklahoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oklahoma filed Critical Univ Oklahoma
Application granted granted Critical
Publication of DK0850243T3 publication Critical patent/DK0850243T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK96928073T 1995-08-03 1996-08-02 O-Glycaninhibitorer af selectinmedieret inflammation DK0850243T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51092095A 1995-08-03 1995-08-03
US1779496P 1996-05-15 1996-05-15
US64980296A 1996-05-17 1996-05-17
PCT/US1996/012820 WO1997006176A2 (en) 1995-08-03 1996-08-02 Peptide and o-glycan inhibitors of selectin mediated inflammation

Publications (1)

Publication Number Publication Date
DK0850243T3 true DK0850243T3 (da) 2004-02-02

Family

ID=27360885

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96928073T DK0850243T3 (da) 1995-08-03 1996-08-02 O-Glycaninhibitorer af selectinmedieret inflammation

Country Status (11)

Country Link
EP (1) EP0850243B1 (es)
JP (1) JPH11510543A (es)
KR (1) KR100523506B1 (es)
AT (1) ATE251636T1 (es)
AU (1) AU723262B2 (es)
CA (1) CA2228512A1 (es)
DE (1) DE69630307T2 (es)
DK (1) DK0850243T3 (es)
ES (1) ES2208759T3 (es)
MX (1) MXPA98000968A (es)
WO (1) WO1997006176A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US20030143662A1 (en) 1998-06-16 2003-07-31 Cummings Richard D. Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
US6593459B1 (en) 1998-06-16 2003-07-15 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
CA2347119A1 (en) * 1998-10-30 2000-05-11 Genetics Institute, Inc. Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
JP2002530425A (ja) * 1998-11-21 2002-09-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 炎症を処置する際のコア２ＧｌｃＮＡｃトランスフェラーゼインヒビターの使用
US6492152B1 (en) 1999-06-15 2002-12-10 The Board Of Regents Of The University Of Oklahoma Core 1 β3-galactosyl transferases and methods of use thereof
US7256171B1 (en) 1999-11-20 2007-08-14 The Regents Of The University Of California Use of core 2 G1cNAc transferase inhibitors in treating inflammation
WO2002022820A1 (en) * 2000-09-12 2002-03-21 Genetics Institute, Llc Inhibition of stenosis or restenosis by p-selectin antagonists
EP1406930A4 (en) * 2000-12-29 2007-01-10 Savient Pharmaceuticals Inc "ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF"
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
AU2003255337A1 (en) * 2002-07-31 2004-02-23 Kylix B.V. Use of genes identified to be involved in tumor development for the development of anti-cancer drugs
JP4599027B2 (ja) * 2002-10-30 2010-12-15 東洋水産株式会社 Ｌ−セレクチン結合阻害剤
FI20021989A0 (fi) * 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
ES2655833T3 (es) 2004-05-11 2018-02-21 AbGenomics Coöperatief U.A. Epítopos que inducen la muerte de células T
GB0513883D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
WO2007067983A2 (en) * 2005-12-09 2007-06-14 Wyeth Sulfotyrosine specific antibodies and uses therefor
JP5331293B2 (ja) * 2006-04-28 2013-10-30 公益財団法人野口研究所 多様性を表現するオリゴ糖またはその誘導体
SI2321235T1 (sl) * 2008-09-02 2019-11-29 Construction Research & Technology Gmbh Uporaba sestavka za pospeševanje strjevanja, ki vsebuje mehčalec
US20120207737A1 (en) * 2009-10-21 2012-08-16 University Of Zurich Medical utility of glycan-binding proteins and glycans
SG10201604767TA (en) 2011-06-13 2016-08-30 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies and uses thereof
KR102630011B1 (ko) 2017-01-11 2024-01-26 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
JP7211961B2 (ja) 2017-03-14 2023-01-24 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡに結合する抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU681369B2 (en) * 1992-11-16 1997-08-28 Board Of Regents Of The University Of Oklahoma, The Glycoprotein ligand for P-selectin and methods of use thereof
WO1995030001A2 (en) * 1994-04-28 1995-11-09 Genetics Institute, Inc. Novel p-selectin ligand protein

Also Published As

Publication number Publication date
KR100523506B1 (en) 2005-10-24
DE69630307D1 (de) 2003-11-13
DE69630307T2 (de) 2004-07-15
EP0850243B1 (en) 2003-10-08
JPH11510543A (ja) 1999-09-14
WO1997006176A3 (en) 1997-07-24
ES2208759T3 (es) 2004-06-16
EP0850243A2 (en) 1998-07-01
AU6766996A (en) 1997-03-05
AU723262B2 (en) 2000-08-24
KR20040039440A (ko) 2004-05-10
CA2228512A1 (en) 1997-02-20
ATE251636T1 (de) 2003-10-15
WO1997006176A2 (en) 1997-02-20
MXPA98000968A (es) 2002-07-15

Similar Documents

Publication Publication Date Title
DK0850243T3 (da) O-Glycaninhibitorer af selectinmedieret inflammation
AU6210698A (en) Carbohydrate mixture
Vieira et al. Structure of a fucose-branched chondroitin sulfate from sea cucumber. Evidence for the presence of 3-O-sulfo-beta-D-glucuronosyl residues
Lamblin et al. Primary structure determination of five sialylated oligosaccharides derived from bronchial mucus glycoproteins of patients suffering from cystic fibrosis. The occurrence of the NeuAc alpha (2----3) Gal beta (1----4)[Fuc alpha (1----3)] GlcNAc beta (1----.) structural element revealed by 500-MHz 1H NMR spectroscopy.
CA2110386A1 (en) Method for the Enzymatic Synthesis of Alpha-Sialylated Oligosaccharide Glycosides
Ray et al. The effect of auxin on synthesis of oat coleoptile cell wall constituents
NZ512751A (en) Fibre blend for enteral composition
MY124548A (en) Synthetic polysaccharides, preparation method therefor and pharmaceutical compositons containing same
ES2055270T3 (es) Uso de l-azucares para la fabricacion de composiciones laxantes.
Klein et al. The broad diversity of neutral and sialylated oligosaccharides derived from human salivary mucins
Wieruszeski et al. Structure of two new oligosaccharides isolated from human milk: sialylated lacto-N-fucopentaoses I and II
Lloyd et al. Immunochemical studies on blood groups. XXXVII. The structures of difucosyl and other oligosaccharides produced by alkaline degradation of blood group A, B, and H substances. Optical rotatory dispersion and circular dichroism spectra of these oligosaccharides
AU4691285A (en) Membrane polysaccharides
ITMI912310A1 (it) Dermatan solfato ad alto titolo, dotato di elevata attivita' trombolitica, e forme farmaceutiche che lo contengono.
Degroote et al. Sulfated oligosaccharides isolated from the respiratory mucins of a secretor patient suffering from chronic bronchitis
AU3266797A (en) Synthetic polysaccharides, method for preparing same and pharmaceutical compositions containing said polysaccharides
WO1997021416A3 (es) Glicoconjugados de substancias opiaceas
Savage et al. Structural characterization of sialylated tetrasaccharides and pentasaccharides with blood group H and Lex activity isolated from bovine submaxillary mucin
Hellerqvist et al. Structural studies of the O-specific side-chains of the cell-wall lipopolysaccharide from Salmonella senftenberg
Rahman et al. The structure of the capsular polysaccharide from a swarming strain of pathogenic Proteus vulgaris
Tyler et al. Specific capsular polysaccharide of type VII Pneumococcus
Fievre et al. Primary structure of a trisialylated oligosaccharide from human milk
Palatnik et al. Partial chemical characterization of the carbohydrate moieties in Leishmania adleri glycoconjugates
Backinowsky et al. Synthesis of oligosaccharide fragments of Shigella flexneri O-specific polysaccharides. The synthesis of two branched trisaccharides.
Christian et al. The use of one-bond, heteronuclear coupling constants (1J—C, H) as structure reporters in 13 CN. MR of oligosaccharides containing 3-deoxy-(= D)-manno-2-octulosonic acid